Medicenna Therapeutics Corp Statistics
Want to see TSE:MDNA full AI Analyst Report?
Medicenna Therapeutics Corp (MDNA) Stock Statistics & Valuation Metrics
Total Valuation
Medicenna Therapeutics Corp has a market cap or net worth of CAD 29.88M. The enterprise value is CAD 28.64M.
- Market Cap
- CAD 29.88M
- Enterprise Value
- CAD 28.64M
Share Statistics
Medicenna Therapeutics Corp has 77,617,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 77,617,340
- Owned by Insiders
- 16.07%
- Owned by Institutions
- 0.15%
Financial Efficiency
Medicenna Therapeutics Corp’s return on equity (ROE) is -7.42 and return on invested capital (ROIC) is -725.41%.
- Return on Equity (ROE)
- -7.42
- Return on Assets (ROA)
- -2.18
- Return on Invested Capital (ROIC)
- -725.41%
- Return on Capital Employed (ROCE)
- -7.93
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.23M
- Employee Count
- 15
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Medicenna Therapeutics Corp is -1.75. Medicenna Therapeutics Corp’s PEG ratio is 0.05.
- PE Ratio
- -1.75
- PS Ratio
- 0.00
- PB Ratio
- 19.94
- Price to FCF
- -2.09
- Price to Operating Cash Flow
- -1.77
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Medicenna Therapeutics Corp had revenue of 0 and earned -18.41M in profits. Earnings per share was -0.22.
- Revenue
- 0
- Gross Profit
- -77.00K
- Operating Income
- -23.71M
- Pretax Income
- -19.70M
- Net Income
- -18.41M
- EBITDA
- -23.64M
- Earnings Per Share (EPS)
- -0.22
Cash Flow
In the last 12 months, operating cash flow was -18.81M and capital expenditures 9.44M, giving a free cash flow of -14.33M billion.
- Operating Cash Flow
- -18.81M
- Free Cash Flow
- -14.33M
- Free Cash Flow per Share
- -0.17
Dividends & Yields
Medicenna Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -47.96%
- Earnings Yield
- -55.65%
Stock Price Statistics
- Beta
- 1.80
- 52-Week Price Change
- -71.90%
- 50-Day Moving Average
- 0.42
- 200-Day Moving Average
- 0.52
- Relative Strength Index (RSI)
- 41.89
- Average Volume (3m)
- 49.87K
Important Dates
Medicenna Therapeutics Corp upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Medicenna Therapeutics Corp as a current ratio of 1.52, with Debt / Equity ratio of 4.79%
- Current Ratio
- 1.52
- Quick Ratio
- 1.52
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.26
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Medicenna Therapeutics Corp has paid -1.29M in taxes.
- Income Tax
- -1.29M
- Effective Tax Rate
- 0.07
Enterprise Valuation
Medicenna Therapeutics Corp EV to EBITDA ratio is -1.06, with an EV/FCF ratio of -1.70.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.06
- EV to Free Cash Flow
- -1.70
- EV to Operating Cash Flow
- -1.29
Balance Sheet
Medicenna Therapeutics Corp has CAD 5.69M in cash and marketable securities with CAD 104.00K in debt, giving a net cash position of CAD 5.59M billion.
- Cash & Marketable Securities
- CAD 5.69M
- Total Debt
- CAD 104.00K
- Net Cash
- CAD 5.59M
- Net Cash Per Share
- CAD 0.07
- Tangible Book Value Per Share
- CAD 0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Medicenna Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -33.27%
Scores
- Smart Score
- ―
- AI Score
- 44
